Related Experiment Video

Updated: May 24, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

EGFR/HER-targeted therapeutics in ovarian cancer

Jason A Wilken1, Tayf Badri, Sarah Cross

  • 1Yale University, Department of Obstetrics, Gynecology & Reproductive Sciences, New Haven, CT 06520, USA.

Future Medicinal Chemistry
|March 16, 2012
PubMed

Insights

Human epidermal growth factor receptor (HER) targeted therapies show promise for epithelial ovarian cancer, but challenges remain. Further research is needed to improve survival rates for these patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epithelial ovarian cancer survival has seen minimal improvement despite advances in treatment.
  • Targeted therapies, particularly those inhibiting the human epidermal growth factor receptor (EGFR/HER/ErbB) family, have significantly improved outcomes in other cancers.
  • The EGFR/HER/ErbB family is implicated in the development and progression of epithelial ovarian cancer.

Purpose of the Study:

  • To review the current literature on HER-targeted therapeutics for epithelial ovarian cancer.
  • To discuss novel HER-targeted agents in clinical development for ovarian cancer.
  • To identify challenges hindering the clinical application of these inhibitors.

Main Methods:

  • Systematic review of published studies on HER-targeted therapies in ovarian cancer.
  • Analysis of clinical trial data for novel HER-targeted therapeutics.
  • Evaluation of factors limiting the efficacy and use of HER inhibitors.

Main Results:

  • Several HER-targeted therapeutics are approved for other cancers, but none for ovarian cancer.
  • Ongoing research is exploring novel HER-targeted agents for ovarian cancer treatment.
  • Challenges such as resistance mechanisms and toxicity have limited their widespread use.

Conclusions:

  • HER-targeted therapies represent a promising avenue for improving epithelial ovarian cancer treatment.
  • Overcoming current challenges is crucial for the successful clinical implementation of these targeted agents.
  • Further investigation into novel HER inhibitors and combination strategies is warranted.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...